American Association for Cancer Research
Browse
21598290cd130696-sup-120170_2_supp_0_nbvjl6.pdf (69.95 kB)

Supplementary Figure 1 from l-2-Hydroxyglutarate: An Epigenetic Modifier and Putative Oncometabolite in Renal Cancer

Download (69.95 kB)
journal contribution
posted on 2023-04-03, 20:47 authored by Eun-Hee Shim, Carolina B. Livi, Dinesh Rakheja, Jubilee Tan, Daniel Benson, Vishwas Parekh, Eun-Young Kho, Arindam P. Ghosh, Richard Kirkman, Sadanan Velu, Shilpa Dutta, Balachandra Chenna, Shane L. Rea, Robert J. Mishur, Qiuhua Li, Teresa L. Johnson-Pais, Lining Guo, Sejong Bae, Shi Wei, Karen Block, Sunil Sudarshan

Supplementary Figure 1. A498 cells were stable transduced with the indicated construct. Protein lysates were harvested and immunoblotted for the indicated proteins.

History

ARTICLE ABSTRACT

Through unbiased metabolomics, we identified elevations of the metabolite 2-hydroxyglutarate (2HG) in renal cell carcinoma (RCC). 2HG can inhibit 2-oxoglutaratre (2-OG)–dependent dioxygenases that mediate epigenetic events, including DNA and histone demethylation. 2HG accumulation, specifically the d enantiomer, can result from gain-of-function mutations of isocitrate dehydrogenase (IDH1, IDH2) found in several different tumors. In contrast, kidney tumors demonstrate elevations of the l enantiomer of 2HG (l-2HG). High-2HG tumors demonstrate reduced DNA levels of 5-hydroxymethylcytosine (5hmC), consistent with 2HG-mediated inhibition of ten-eleven translocation (TET) enzymes, which convert 5-methylcytosine (5mC) to 5hmC. l-2HG elevation is mediated in part by reduced expression of l-2HG dehydrogenase (L2HGDH). L2HGDH reconstitution in RCC cells lowers l-2HG and promotes 5hmC accumulation. In addition, L2HGDH expression in RCC cells reduces histone methylation and suppresses in vitro tumor phenotypes. Our report identifies l-2HG as an epigenetic modifier and putative oncometabolite in kidney cancer.Significance: Here, we report elevations of the putative oncometabolite l-2HG in the most common subtype of kidney cancer and describe a novel mechanism for the regulation of DNA 5hmC levels. Our findings provide new insight into the metabolic basis for the epigenetic landscape of renal cancer. Cancer Discov; 4(11); 1290–8. ©2014 AACR.This article is highlighted in the In This Issue feature, p. 1243

Usage metrics

    Cancer Discovery

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC